GLP-1 Dosing Schedules: Why You Start Low, How Fast to Step Up, and What to Do After a Missed Dose

Every GLP-1 label begins the same way: you start on a small dose that does little for weight or blood sugar, stay on it for about a month, and then move up in steps. Researchers at the University of Texas Medical Branch (UTMB) wanted to know how often doctors skip that advice in everyday practice, and what happens to patients when they do.

Their study, published in Diabetes, Obesity and Metabolism on October 19, 2026, used MarketScan insurance claims from 2018 to 2021. It followed 48,658 American adults with diabetes, obesity, or both who were starting semaglutide shots and had no record of earlier incretin treatment, the drug family that includes GLP-1 medicines. Although the label's starting dose is 0.25 mg a week, the study counted any start of 0.5 mg or less as low and 1.0 mg or more as high, and 14.5% of people began high. That group had a 25% higher risk of stopping early (hazard ratio 1.25) and was less likely to still be on the drug a year later, a gap that held after the authors accounted for age, obesity, other illnesses, and cost.

A claims study can show a link but cannot prove that the high start made people quit, and the data end in 2021, years before the Wegovy pill and Foundayo existed. Still, the finding matches what the labels themselves say about why the schedule exists: the slow climb is there to protect your stomach, so that you stay on the drug long enough for it to work. Most of the other rules in this guide, including what to do after a missed dose, follow from that goal and from how long each drug stays in your body. Everything below comes from the current FDA labels, and your prescriber may adjust it for your situation.

Stomach problems such as nausea, vomiting, and diarrhea are the most common side effects of these drugs, and they tend to cluster in the early months. The Ozempic label says most reports of those problems came during dose escalation, the weeks when the dose is being raised. The Zepbound label says the same and adds that they decreased over time, and the Foundayo label reports a similar pattern. In the Wegovy injection weight-loss trials, 44% of people taking the drug had nausea, compared with 16% of those given placebo, a dummy shot.

Some starting doses are not meant to treat anything at all. The Rybelsus label says its 3 mg starting tablet "is not effective for glycemic control," and the Zepbound label says the 2.5 mg starting dose "is not approved as a maintenance dosage." Their job is to give your digestive system time to adjust before you reach the dose that does the real work.

Losing fluids from vomiting or diarrhea carries a second risk. The Wegovy, Zepbound, and Foundayo labels describe reports of sudden kidney injury in people who became dehydrated, and they ask doctors to watch kidney function most closely when treatment starts and each time the dose goes up. For more on what helps with these side effects, see our guide to why people quit GLP-1 drugs.

The table lists the step-up schedule from each U.S. label as of October 2026. "Weekly" drugs are shots taken once a week; the rest are pills taken once a day.

The math sets a floor on how fast anyone can reach the top. On Wegovy shots, the earliest you can reach 2.4 mg is week 17, while Zepbound has five steps, so 15 mg cannot start before week 21, and Foundayo's six dose levels put 17.2 mg at day 151 at the soonest. The words "at least" in most of these labels mean the waiting periods are minimums, and nothing in them says you must keep climbing on schedule.

The top dose is also not a target that everyone has to hit. The Zepbound label lists 5 mg, 10 mg, and 15 mg as maintenance doses for weight loss, Wegovy's label allows 1.7 mg or 2.4 mg, and the Ozempic and Mounjaro labels call for a higher dose only if blood sugar needs more control. The Rybelsus label also covers a newer product, Ozempic tablets, which start at 1.5 mg and go up to 4 mg and, if needed, 9 mg; the two tablets are not interchangeable milligram for milligram.

The FDA approved a 7.2 mg weekly dose of Wegovy, sold as Wegovy HD, on March 19, 2026. The label limits it to adults with obesity who have taken 2.4 mg for at least 4 weeks without problems and who need to lose more weight, and its safety has not been established in children and teenagers or in people with the liver disease MASH.

The higher dose brings a side effect that most people have not heard of. Dysesthesia means altered skin sensations, such as tingling, burning, or skin that hurts to the touch, and in the two 72-week trials behind the approval, 22% of people on 7.2 mg reported it, compared with 6% on 2.4 mg and 0.3% on placebo. Most of those who had their dose lowered or paused recovered, but among 38 people who went back up to 7.2 mg after recovering, 17 (45%) had the symptoms return. Hair loss was also more common, reported by 5.8% of people on 7.2 mg compared with 3.3% on 2.4 mg.

If a new dose makes you sick, the Wegovy label tells doctors to consider waiting another 4 weeks before the next step. The Wegovy pill label offers the same option, and if the 25 mg pill is too hard to tolerate, it suggests switching to the 1.7 mg shot instead. The Zepbound label says to consider a lower maintenance dose if a higher one causes trouble, so staying on a dose for an extra month, or stopping short of the top, fits within the label. Taking less than the lowest labeled dose is a different matter, which our piece on microdosing covers.

Each step up can also matter for birth control. The Zepbound and Mounjaro labels advise people using birth control pills to switch to a non-oral method or add a barrier method, such as condoms, for 4 weeks after starting and for 4 weeks after each dose increase, and Foundayo's label gives the same advice for 30 days. The labels explain that these drugs can make birth control pills less effective, and the Zepbound label links this to slower stomach emptying, which is largest after the first dose. Every extra step adds another of those windows, so it helps to plan ahead. Our birth control and pregnancy guide has more detail.

The rules for a missed dose depend on how long each drug stays in the blood. Semaglutide, the drug in Wegovy, Ozempic, and Rybelsus, has a half-life of about a week, which means that about half of a dose is still in the blood seven days later. Tirzepatide, the drug in Zepbound and Mounjaro, has a half-life of 5 to 6 days, while orforglipron, the drug in Foundayo, is cleared much faster, with a half-life of about 29 to 49 hours.

Wegovy and Ozempic word the rule differently, but because both are weekly shots, the windows line up: taking a late shot up to 5 days after the missed day still leaves at least 2 days before the next one. Zepbound and Mounjaro have a shorter window, and their patient guides add a firm limit, which is to never take two doses within 3 days (72 hours) of each other. Similar spacing applies if you want to move your shot to a different day of the week, since Ozempic and Wegovy require at least 2 days since the last dose and Zepbound and Mounjaro require 3.

After a skipped dose, each label sends you back to your usual schedule, and none of them tells you to double up to make up for the dose you missed.

Some gaps last longer than a week, because a pharmacy runs out, insurance lapses, or a stomach bug makes a shot unthinkable. The Wegovy shot label is specific: after 2 or more missed weekly doses in a row, restart the climb at a lower dose to reduce the risk of stomach side effects, and the patient guide tells you to call your prescriber to work out how. Foundayo sets the line at 7 or more missed daily doses in a row.

The Ozempic, Zepbound, and Mounjaro labels do not give a number for a longer gap, which is a good reason to call before your next dose. The Wegovy and Foundayo labels call for climbing again after a long break, and jumping straight back to a full dose resembles the high-dose starts that the UTMB researchers linked to quitting early.

Switching between a shot and a pill follows its own timing. A person on the 2.4 mg Wegovy shot can start the 25 mg Wegovy pill one week after the last shot, and going the other way, the 2.4 mg shot starts the day after the last pill. Someone on the 0.5 mg Ozempic shot can move to 7 mg or 14 mg of Rybelsus one week after the last injection. Our comparison of Foundayo and the Wegovy pill covers how the two daily pills differ.

If your first prescription is for anything above the label's starting dose, ask why. In the UTMB data, high starts were more likely among men and younger patients, in the West and South, and when an endocrinologist wrote the prescription. A doctor may have a reason, such as a patient who has taken a GLP-1 drug before, and it is fair to ask to hear it.

It also helps to agree on a plan before trouble starts: what happens if a step makes you sick, who to call if you miss two weekly doses, and what dose would count as good enough for you. The labels set minimum waits between steps rather than deadlines, and the Wegovy and Zepbound labels both name lower doses that people can stay on for the long term.